Serum HE4 and CA125 combined to predict and monitor recurrence of type II endometrial carcinoma

Abstract

There is no recognized serum biomarker to predict the recurrence of endometrial carcinoma (EC). We aimed to explore serum human epididymis protein 4 (HE4) and cancer antigen 125 (CA125) as the biomarkers to predict and monitor recurrence of type II EC. 191 patients diagnosed with type II EC were involved for this retrospective study. Comparing recurrent with non-recurrent patients, HE4 levels resulted a statistically significant difference at primary diagnosis and recurrence, respectively (P = 0.002 and P = < 0.001), while CA125 levels resulted statistically significant (P = < 0.001) at recurrence. According to receiver operating characteristic curve analysis, the areas under the curve were significant for HE4 levels at primary diagnosis and recurrence predicting recurrence. Furthermore, CA125 levels at recurrence were significant. And the combination of both markers showed the higher sensitivity and specificity than single one. Patients with higher HE4 levels were associated with worse disease-free survival and overall survival, the opposite was true for patients with lower HE4 levels. The preoperative HE4 levels could be used to evaluate the risk factors of type II EC. Which suggested that HE4 levels might associated with the prognosis of type II EC. And combination of HE4 and CA125 could be applied to monitor recurrence during follow-up.

Preoperative Prediction Value of Pelvic Lymph Node Metastasis of Endometrial Cancer: Combining of ADC Value and Radiomics Features of the Primary Lesion and Clinical Parameters

“…In clinical practice, CA125 has been routinely used to diagnose a variety of malignancies, especially epithelial ovarian cancer [ 28 ]. Quan et al [ 29 ] demonstrated that serum CA125 significantly correlated with clinicopathological risk factors, such as depth of myometrial invasion, LN status, and FIGO stage and that CA125 is a promising prognostic indicator for EC [ 30 , 31 ]. In our study, CA125 could be used as an independent predictor of PLNM in EC patients, which is consistent with the results of Lei et al [ 32 ].…”

Endometrial thickness and uterine artery Doppler parameters as soft markers for prediction of endometrial cancer in postmenopausal bleeding women: a cross-sectional study at tertiary referral hospitals from Vietnam

“…Recently, several studies have mentioned the role of serum cancer antigen (CA)-125 in predicting EC [ 38 , 39 ]. Therefore, we hope to develop a better study design in order to provide predictive modeling of EC and cancer stage based on well-known clinical risk factors (body mass index, postmenopausal age, hypertension, and diabetes) combined with endometrial thickness, Doppler UtA indices, and CA-125 [ 40 ].…”

Prognostic values of human epididymis protein 4 expression in patients with endometrial cancer: A systematic review and meta‐analysis

“…The flow chart of literature screening is shown in Figure 1. among these studies, eight were from China, [7][8][9][10][11][12][13][14] four from Italy, [15][16][17][18] four from Poland, [19][20][21][22] three from Iran, [23][24][25] two from Australia, 26,27 two from Czech Republic, 28,29 two from Egypt, 30,31 two from Thailand, 32,33 two from The Netherlands, 34,35 two from Turkey, 36,37 and one each was from America, Austria, Denmark, India, Ireland, Slovenia, and Spain. [38][39][40][41][42][43][44] Thirty-three studies described the relationship between serum HE4 levels and the clinicopathological characteristics of EC, three studies described the relationship between tissue HE4 expression and the clinicopathological characteristics of EC, and two studies examined HE4 expression in both samples.…”